The Primate Corpus Luteum: Functional Regression and Cardiovascular Impacts
The Primate Corpus Luteum: Functional Regression and Cardiovascular Impacts
批准号:
8230492
负责人:
Randy L Bogan
金额:
$8.8万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-01 至 2012-09-20
关键词:
AddressAffectAgeAgonistApoptosisAreaAssisted Reproductive TechnologyBile AcidsBile fluidBindingBiological AssayCardiovascular DiseasesCardiovascular PhysiologyCardiovascular systemCellsCholesterolCholesterol HomeostasisChorionic GonadotropinClinicalClinical ResearchConceptionsDNA Microarray ChipDataDefectDevelopmentDiseaseDrug FormulationsEnsureEnvironmentEstradiolExperimental ModelsFemaleFunctional disorderGene ExpressionGene TargetingGenesGoalsGonadal Steroid HormonesHealthHigh Density LipoproteinsHormonal Oral ContraceptivesHormone replacement therapyHumanHuman Chorionic GonadotropinImplantIn VitroIndividualInfusion proceduresInvestigationKnowledgeLaboratoriesLigandsLipidsLipoprotein ReceptorLipoproteinsLiverLongevityLow-Density LipoproteinsLuteal CellsLuteal PhaseLuteolysisMacaca mulattaMeasuresMediator of activation proteinMedicalMenstrual cycleMenstruationMentorsMetabolismModelingMolecularMonkeysOregonOrganOutputOvarianOvaryPeripheralPhasePhysiologyPlayPostdoctoral FellowPostmenopausePregnancyPregnancy MaintenancePregnancy RatePregnancy lossPremenopausePrimatesProbabilityProductionProgesteronePromoter RegionsProtein IsoformsProteinsProtocols documentationPublishingReceptor ActivationReceptor SignalingRecruitment ActivityRegulationReproductionReproductive HealthReproductive PhysiologyResearchResearch PersonnelResearch TrainingRiskRisk FactorsRoleSerumSheepSignal TransductionSimulateSteroidsSupplementationSystemTestingTrainingTriglyceridesVery low density lipoproteinWomanWorkactivity markerassisted reproductionbasecardiovascular disorder riskcardiovascular risk factorcareercareer developmentcell growth regulationcorpus luteumexperienceextracellulargenome-wideimprovedin vivointerestintraovarianlipoprotein triglyceridemeetingsmennonhuman primatenovelpost-doctoral trainingprematurepreventreceptorreproductiveresearch studyreverse cholesterol transportsensorskillssteroid hormonesuccessuptake
中文摘要
描述(申请人提供):候选人兰迪·博根博士是俄勒冈州国家灵长类动物研究中心(ONPRC)博士后研究员。博根博士的研究生研究利用绵羊作为实验模型,研究黄体(CL)合成孕酮(P4)的机制。在这段经历中,博根博士对将他的研究应用于人类健康产生了兴趣。因此,他来到ONPRC进行博士后培训,以进一步提高他在使用翻译相关的非人类灵长类动物模型调控哺乳动物CL方面的专业知识。在怀孕的前6-7周,从CL产生的P4是维持妊娠所必需的,在此期间妊娠丢失的概率与P4水平成反比。因此,了解黄体期结束时灵长类CL停止P4产生的机制(称为功能回归),对于预防早期妊娠丢失,提高辅助生殖技术的效率具有重要意义。然而,导致灵长类CL功能退化的机制尚不清楚。这位候选人先前发现,在灵长类CL中,反向胆固醇转运(RCT)系统是功能退化和最终黄体溶解(完全结构退化)的潜在中介。由于RCT系统的研究也对心血管疾病有影响,他还发现恒河猴在月经周期的不同阶段脂蛋白水平的变化与心血管疾病风险的降低是一致的。这些变化可能是由于卵巢对脂蛋白代谢的直接影响,和/或卵巢分泌的类固醇对肝脏或其他器官产生全身影响。根据候选人的长期职业目标,即成为一名生殖生理学的独立研究员,以帮助改善人类的生殖健康,候选人确定了三个直接领域,以确保作为一名独立研究员的成功:1)进一步发展关于心血管疾病及其风险因素研究的研究专长,2)获得进行临床研究所需的知识和技能,以及3)获得足够的经验,以便进行有效的实验室管理。这项提议将利用OHSU的科学环境,OHSU拥有仅有的八个国家灵长类研究中心之一,以及一个可以进行临床研究和培训的医学园区。具有非人灵长类和临床研究经验的生殖和心血管生理学领域的专家已经被招募来监督候选人的培训和研究。为实现上述近期目标,制定了正式课程和培训目标。这项研究计划将解决一个新的假设,即受肝脏X受体(LXR)1和/或2调节的胆固醇摄取和外流活动决定黄体类固醇生成寿命,并降低发生心血管疾病的风险。为了验证这一假设,在K99指导阶段进行的第一个目标将使用分子研究来确定LXR1和LXR2在灵长类CL退化过程中诱导RCT系统的个体重要性,体外研究将确定由两种或单独的LXR亚型激活所诱导的灵长类CL基因表达的全基因组变化。在体内自发的黄体溶解过程中,将确定每个LXR亚型与已知LXR靶基因的启动子区域的直接结合,并在LXR激动剂存在的情况下,对含有这两种或单个LXR亚型的黄体细胞进行DNA微阵列分析。独立阶段的研究包括目标2和目标3。第二个目标将利用在CL内直接输注合成的LXR激动剂来确定RCT系统的过早激活是否会缩短CL的寿命。此外,我们将确定模拟早孕是否可以防止LXR激活和RCT,这通常是在非受孕周期结束时观察到的,以及LXR激动剂替代是否可以逆转绒毛膜促性腺激素(CG)的作用。血清雌二醇(E2)和P4水平,以及月经第一天的水平,将被用作黄体寿命的标志。测定已知的LXR靶基因和脂蛋白受体的表达、内源性LXR配体水平和脂质定位将提供RCT活性的评估,而细胞凋亡的标志物将评估CL结构的完整性。第三个具体目标将利用恒河猴来确定由E2和P4周期性水平引起的心血管危险因素的变化,而不是由卵巢内直接作用引起的变化。去卵巢的猴子将接受E2和P4植入,以模拟人工月经周期,并将测量血清中高密度脂蛋白(高密度脂蛋白)、低密度脂蛋白(低密度脂蛋白)和极低密度脂蛋白(极低密度脂蛋白)和甘油三酯的水平,作为心血管风险的指标。此外,还将使用女性进行实验,以确定月经周期引起的心血管风险因素的变化,以及通过荷尔蒙口服避孕药抑制卵巢活动如何影响这些因素。这项工作是独一无二的,因为RCT系统还没有在任何物种的CL中被研究过,它可能是导致灵长类CL功能退化的尚未识别的信号。此外,还将探索这些发现的跨学科影响,这些发现可能会产生与减少女性心血管疾病以及更安全地使用荷尔蒙口服避孕药和激素替代疗法相关的重要发现。
英文摘要
DESCRIPTION (provided by applicant): The candidate, Dr. Randy Bogan, is a postdoctoral fellow at the Oregon National Primate Research Center (ONPRC). Dr. Bogan's graduate research utilized sheep as an experimental model to study mechanisms controlling the synthesis of progesterone (P4) by the corpus luteum (CL). During this experience, Dr. Bogan developed an interest in the applications of his research to human health. Therefore, he came to the ONPRC to conduct postdoctoral training that would further his expertise in the regulation of the mammalian CL using a translationally-relevant nonhuman primate model. P4 production from the CL is required to maintain pregnancy in women through the first 6-7 weeks of gestation with the probability of pregnancy loss during this period being inversely related to P4 levels. Therefore, understanding the mechanisms that halt P4 production (termed functional regression) in the primate CL at the end of the luteal phase has implications for preventing early pregnancy loss, and improving the efficiency of assisted reproduction technologies. However, the mechanisms causing functional regression of the primate CL are not known. The candidate previously identified the reverse cholesterol transport (RCT) system as a potential mediator of functional regression and ultimately luteolysis (complete structural degradation) in the primate CL. As study of the RCT system also has implications for cardiovascular disease, he additionally discovered changes in lipoprotein levels in rhesus macaques at distinct phases of the menstrual cycle that are consistent with a reduced risk of developing cardiovascular disease. These changes may be due to direct ovarian effects on lipoprotein metabolism, and/or steroids secreted from the ovary having systemic effects on the liver or other organs. In keeping with the candidate's long term career goal of becoming an independent investigator in reproductive physiology to help improve the reproductive health of humans, the candidate has identified three immediate areas where additional training is needed to ensure success as an independent investigator: 1) further develop research expertise regarding the study of cardiovascular disease and its risk factors, 2) obtain the necessary knowledge and skills to conduct clinical research, and 3) gain sufficient experience to allow for effective laboratory management. This proposal will take advantage of the scientific environment at OHSU, which has one of only eight National Primate Research Centers, as well as a medical campus where clinical research and training can be performed. Experts in the fields of reproduction and cardiovascular physiology, with both nonhuman primate and clinical research experience, have been recruited to oversee the candidate's training and research. Formal classes and training objectives are laid out to meet the aforementioned immediate goals. The research plan will address the novel hypothesis that cholesterol uptake and efflux activities, regulated by liver x receptor (LXR) 1 and/or 2, determine luteal steroidogenic lifespan and reduce the risk of developing cardiovascular disease. To test this hypothesis, the first aim conducted during the K99 mentored phase will use molecular studies to determine the individual importance of LXR1 and LXR2 in inducing the RCT system during regression of the primate CL, and in vitro studies will identify genome-wide changes in gene expression of the primate CL induced by activation of both or individual LXR isoforms. Direct binding of each LXR isoform to promoter regions of known LXR target genes will be determined during spontaneous luteolysis in vivo, and DNA microarray assays will be performed on luteal cells containing both or individual LXR isoforms in the presence of an LXR agonist. The independent phase research includes aims 2 and 3. The second aim will utilize direct infusion of a synthetic LXR agonist within the CL to determine if premature activation of the RCT system can shorten CL lifespan. Also, we will determine if simulating early pregnancy prevents LXR activation and RCT normally observed at the end of non-conception cycles, and whether LXR agonist replacement can reverse the effects of chorionic gonadotropin (CG). Serum levels of estradiol (E2) and P4, as well as the first day of menstruation, will be used as markers of luteal lifespan. Determining the expression of known LXR target genes and lipoprotein receptors, endogenous LXR ligand levels, and lipid localization will provide an assessment of RCT activity, and markers of apoptosis will evaluate CL structural integrity. The third specific aim will utilize rhesus macaques to determine changes in cardiovascular risk factors induced by cyclical levels of E2 and P4, versus those induced by direct intra-ovarian effects. Ovariectomized monkeys will receive E2 and P4 implants to simulate an artificial menstrual cycle and levels of high, low, and very-low density lipoproteins (HDL, LDL, VLDL, respectively) and triglycerides in serum will be measured as indicators of cardiovascular risk. Also, experiments will be performed using women to determine menstrual cycle-induced changes in cardiovascular risk factors and how inhibiting ovarian activity via hormonal oral contraceptives affects these factors. This work is unique as the RCT system has not been investigated in the CL of any species, and it may be the as-yet unidentified signal causing functional regression of the primate CL. Additionally, cross-disciplinary implications of these findings will be explored that may yield important findings with relevance to reducing cardiovascular disease in women and safer administration of hormonal oral contraceptives and hormone replacement therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Primate Corpus Luteum: Functional Regression and Cardiovascular Impacts
-
批准号:8509350
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2011
-
负责人:Randy L Bogan
-
依托单位:
The Primate Corpus Luteum: Functional Regression and Cardiovascular Impacts
-
批准号:8549776
-
项目类别:
-
资助金额:$16.31万
-
财政年份:2011
-
负责人:Randy L Bogan
-
依托单位:
The Primate Corpus Luteum: Functional Regression and Cardiovascular Impacts
-
批准号:8698642
-
项目类别:
-
资助金额:$22.98万
-
财政年份:2011
-
负责人:Randy L Bogan
-
依托单位:
The Primate Corpus Luteum: Functional Regression and Cardiovascular Impacts
-
批准号:8027718
-
项目类别:
-
资助金额:$8.58万
-
财政年份:2011
-
负责人:Randy L Bogan
-
依托单位:
海外基金